Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07430059 | Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | PHASE1 | NOT YET_RECRUITING | 20 | — | — | Apr 1, 2026 | Sep 1, 2026 | Feb 24, 2026 | - | — |
total semaglutide concentration
Maximal semaglutide concentration
Time to reach maximal semaglutide concentration
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Semaglutide Implant (NPM-139) | EXPERIMENTAL | Each participants in this arm will receive one Semaglutide Implant (NPM-139) which will be inserted subcutaneously in the upper outer arm and subsequently removed after 4 weeks of treatment. |
| Semaglutide (Wegovy) weekly injection | ACTIVE_COMPARATOR | Each participant in this arm will receive Semaglutide (Wegovy) 0.25 mg subcutaneous injection weekly for 4 weeks of treatment. |
| Name | Type | Description |
|---|---|---|
| Semaglutide Implant (NPM-139) | COMBINATION_PRODUCT | Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid formulation of semaglutide that is released from the implant at a substantially constant rate over at least 15 weeks. |
| Semaglutide (Wegovy) weekly injection | DRUG | Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL. It is injected SC in the abdomen, thigh or upper arm once/week. |
Inclusion Criteria: * BMI between 27 and 40 kg/m2 (inclusive) * HbA1c \</= 6.0% and FPG \</+ 6.7 mmil/L * eGFR \>/= 60 mL/m2 * No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination Exclusio...